PPARGC1A and facioscapulohumeral muscular dystrophy: We have shown that suppression of PGC1α may drive muscle hypotrophy in FSHD, it is possible that the reported increases in muscle mass under β2-adrenergic stimulation may be driven by up-regulation of PGC1α.